Vânia Hungria

12.5k total citations · 4 hit papers
122 papers, 4.3k citations indexed

About

Vânia Hungria is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Vânia Hungria has authored 122 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Hematology, 63 papers in Oncology and 59 papers in Molecular Biology. Recurrent topics in Vânia Hungria's work include Multiple Myeloma Research and Treatments (104 papers), Protein Degradation and Inhibitors (40 papers) and Peptidase Inhibition and Analysis (23 papers). Vânia Hungria is often cited by papers focused on Multiple Myeloma Research and Treatments (104 papers), Protein Degradation and Inhibitors (40 papers) and Peptidase Inhibition and Analysis (23 papers). Vânia Hungria collaborates with scholars based in Brazil, United States and Spain. Vânia Hungria's co-authors include Andrew Spencer, Katja Weisel, María‐Victoria Mateos, Antonio Palumbo, Pieter Sonneveld, Xiang Qin, Ajay K. Nooka, Saroj Vadhan‐Raj, Roger von Moos and Roger Dansey and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Vânia Hungria

110 papers receiving 4.2k citations

Hit Papers

Daratumumab, Bortezomib, and Dexamethasone for Multiple M... 2011 2026 2016 2021 2016 2011 2020 2024 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    2016 1.1k citations Asher Chanan‐Khan, Katja Weisel et al. profile →
  2. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
    2011 877 citations Vânia Hungria et al. profile →
  3. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    2020 256 citations Shaji Kumar, Simon J. Harrison et al. profile →
  4. Multiple myeloma
    2024 72 citations Paola Neri, Nizar J. Bahlis et al. Nature Reviews Disease Primers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vânia Hungria Brazil 25 2.7k 2.6k 2.3k 447 447 122 4.3k
Jens Hillengaß Germany 36 3.2k 1.2× 1.7k 0.7× 1.9k 0.9× 543 1.2× 515 1.2× 188 4.2k
Ajay K. Nooka United States 36 3.5k 1.3× 3.4k 1.3× 2.9k 1.3× 623 1.4× 551 1.2× 282 6.0k
Thomas Moehler Germany 25 1.4k 0.5× 739 0.3× 1.1k 0.5× 281 0.6× 253 0.6× 69 2.1k
Reiner Bartl Germany 33 1.6k 0.6× 1.1k 0.4× 594 0.3× 839 1.9× 596 1.3× 114 3.5k
Konstantinos Zervas Greece 21 1.4k 0.5× 1.2k 0.5× 937 0.4× 475 1.1× 88 0.2× 61 2.2k
Margaret Macro France 24 1.7k 0.6× 1.8k 0.7× 1.4k 0.6× 720 1.6× 210 0.5× 83 3.6k
Stephen H. Petersdorf United States 29 2.6k 0.9× 1.7k 0.6× 1.2k 0.5× 769 1.7× 918 2.1× 78 4.7k
Rubén Niesvizky United States 45 6.0k 2.2× 4.6k 1.8× 5.6k 2.5× 1.1k 2.5× 507 1.1× 290 9.0k
Marine Diviné France 39 1.8k 0.6× 2.2k 0.9× 974 0.4× 1.3k 2.8× 205 0.5× 112 5.1k
Samantha Pozzi Italy 27 536 0.2× 1.1k 0.4× 853 0.4× 279 0.6× 120 0.3× 91 2.3k

Countries citing papers authored by Vânia Hungria

Since Specialization
Citations

This map shows the geographic impact of Vânia Hungria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vânia Hungria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vânia Hungria more than expected).

Fields of papers citing papers by Vânia Hungria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vânia Hungria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vânia Hungria. The network helps show where Vânia Hungria may publish in the future.

Co-authorship network of co-authors of Vânia Hungria

This figure shows the co-authorship network connecting the top 25 collaborators of Vânia Hungria. A scholar is included among the top collaborators of Vânia Hungria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vânia Hungria. Vânia Hungria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Terpos, Evangelos, Suzanne Trudel, María‐Victoria Mateos, et al.. (2025). Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events. American Journal of Hematology. 100(10). 1839–1850. 2 indexed citations
2.
3.
4.
Filho, João Tadeu Damian Souto, et al.. (2025). Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer Journal. 15(1). 37–37. 1 indexed citations
5.
Hungria, Vânia, et al.. (2024). Brazilian Real-Life Experience of Multiple Myeloma (MMyBRAve): Improvement in Outcomes, But Remaining Diagnostic and Therapeutic Gaps. Clinical Lymphoma Myeloma & Leukemia. 25(1). 26–31. 1 indexed citations
6.
Neri, Paola, Nizar J. Bahlis, Evangelos Terpos, et al.. (2024). Multiple myeloma. Nature Reviews Disease Primers. 10(1). 72 indexed citations breakdown →
7.
8.
Dimopoulos, Meletios Α., Vânia Hungria, Atanas Radinoff, et al.. (2023). S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3). HemaSphere. 7(S3). e072005a–e072005a. 2 indexed citations
9.
10.
Crusoé, Edvan de Queiroz, et al.. (2022). Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life. Hematology Transfusion and Cell Therapy. 45(2). 259–265. 4 indexed citations
11.
Kumar, Shaji, Simon J. Harrison, Michèle Cavo, et al.. (2021). Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood. 138(Supplement 1). 84–84. 20 indexed citations
12.
Usmani, Saad Z., María‐Victoria Mateos, Vânia Hungria, et al.. (2020). Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. Journal of Cancer Research and Clinical Oncology. 147(2). 619–631. 20 indexed citations
13.
Hungria, Vânia, Déborah Martı́nez-Baños, María‐Victoria Mateos, et al.. (2020). Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis. Advances in Therapy. 37(12). 4996–5009. 5 indexed citations
14.
Crusoé, Edvan de Queiroz, et al.. (2019). Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients. Hematology Transfusion and Cell Therapy. 42(2). 159–163. 7 indexed citations
15.
Moreau, Philippe, Simon J. Harrison, Michèle Cavo, et al.. (2019). Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 1888–1888. 28 indexed citations
16.
17.
Crusoé, Edvan de Queiroz, et al.. (2016). Bilateral breast plasmacytoma: a clinical case report. Revista Brasileira de Hematologia e Hemoterapia. 38(2). 166–169. 3 indexed citations
18.
Hungria, Vânia, et al.. (2016). Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies. Revista Brasileira de Hematologia e Hemoterapia. 38(1). 37–43. 4 indexed citations
19.
20.
Gonçalves, Romélia Pinheiro, et al.. (2003). Metabolism of chylomicron-like emulsions in patients with Hodgkin’s and with non-Hodgkin’s lymphoma. Leukemia Research. 27(2). 147–153. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jens Hillengaß Breakdown of academic impact, for papers by Ajay K. Nooka Breakdown of academic impact, for papers by Thomas Moehler Breakdown of academic impact, for papers by Reiner Bartl Breakdown of academic impact, for papers by Konstantinos Zervas Breakdown of academic impact, for papers by Margaret Macro Breakdown of academic impact, for papers by Stephen H. Petersdorf Breakdown of academic impact, for papers by Rubén Niesvizky Breakdown of academic impact, for papers by Marine Diviné Breakdown of academic impact, for papers by Samantha Pozzi
Rankless by CCL
2026